Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Scaffold protein SH3BP2 signalosome is pivotal for immune activation in nephrotic syndrome
Tarak Srivastava, Robert E. Garola, Jianping Zhou, Varun C. Boinpelly, Mohammad H. Rezaiekhaligh, Trupti Joshi, Yuexu Jiang, Diba Ebadi, Siddarth Sharma, Christine Sethna, Vincent S. Staggs, Ram Sharma, Debbie S. Gipson, Wei Hao, Yujie Wang, Laura H. Mariani, Jeffrey B. Hodgin, Robert Rottapel, Teruhito Yoshitaka, Yasuyoshi Ueki, Mukut Sharma
Tarak Srivastava, Robert E. Garola, Jianping Zhou, Varun C. Boinpelly, Mohammad H. Rezaiekhaligh, Trupti Joshi, Yuexu Jiang, Diba Ebadi, Siddarth Sharma, Christine Sethna, Vincent S. Staggs, Ram Sharma, Debbie S. Gipson, Wei Hao, Yujie Wang, Laura H. Mariani, Jeffrey B. Hodgin, Robert Rottapel, Teruhito Yoshitaka, Yasuyoshi Ueki, Mukut Sharma
View: Text | PDF
Research Article Nephrology

Scaffold protein SH3BP2 signalosome is pivotal for immune activation in nephrotic syndrome

  • Text
  • PDF
Abstract

Despite clinical use of immunosuppressive agents, the immunopathogenesis of minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) remains unclear. Src homology 3-binding protein 2 (SH3BP2), a scaffold protein, forms an immune signaling complex (signalosome) with 17 other proteins, including phospholipase Cγ2 (PLCγ2) and Rho-guanine nucleotide exchange factor VAV2 (VAV2). Bioinformatic analysis of human glomerular transcriptome (Nephrotic Syndrome Study Network cohort) revealed upregulated SH3BP2 in MCD and FSGS. The SH3BP2 signalosome score and downstream MyD88, TRIF, and NFATc1 were significantly upregulated in MCD and FSGS. Immune pathway activation scores for Toll-like receptors, cytokine-cytokine receptor, and NOD-like receptors were increased in FSGS. Lower SH3BP2 signalosome score was associated with MCD, higher estimated glomerular filtration rate, and remission. Further work using Sh3bp2KI/KI transgenic mice with a gain-in-function mutation showed ~6-fold and ~25-fold increases in albuminuria at 4 and 12 weeks, respectively. Decreased serum albumin and unchanged serum creatinine were observed at 12 weeks. Sh3bp2KI/KI kidney morphology appeared normal except for increased mesangial cellularity and patchy foot process fusion without electron-dense deposits. SH3BP2 co-immunoprecipitated with PLCγ2 and VAV2 in human podocytes, underscoring the importance of SH3BP2 in immune activation. SH3BP2 and its binding partners may determine the immune activation pathways resulting in podocyte injury leading to loss of the glomerular filtration barrier.

Authors

Tarak Srivastava, Robert E. Garola, Jianping Zhou, Varun C. Boinpelly, Mohammad H. Rezaiekhaligh, Trupti Joshi, Yuexu Jiang, Diba Ebadi, Siddarth Sharma, Christine Sethna, Vincent S. Staggs, Ram Sharma, Debbie S. Gipson, Wei Hao, Yujie Wang, Laura H. Mariani, Jeffrey B. Hodgin, Robert Rottapel, Teruhito Yoshitaka, Yasuyoshi Ueki, Mukut Sharma

×

Figure 8

Western blot analysis using total protein lysate from human podocytes.

Options: View larger image (or click on image) Download as PowerPoint
Western blot analysis using total protein lysate from human podocytes.
(...
(A) Western blotting of protein lysate from human podocytes, mouse podocytes, and mouse mesangial cells shows expression of SH3BP2 protein in podocytes and mesangial cells. (B) Western blotting for SH3BP2 was performed with antibody for SH3BP2 (sc-377020, Santa Cruz Biotechnology, and antibody provided as a gift from University of Toronto, Toronto, Ontario, Canada) in different concentrations to optimize the immunoprecipitation experiments. Western blotting showed presence of SH3BP2 in human podocyte cell lysate and its immunoprecipitation with both antibodies. (C) The Western blot showing presence of SH3BP2, PLCγ2, and VAV2 in human podocytes. Anti-SH3BP2 antibody (from University of Toronto, Toronto, Ontario, Canada) pulled down VAV2 and PLCγ2. The lanes were run on the same gel but were noncontiguous (separated by black line). (D) Immunoprecipitation with VAV2 (sc-271442) antibody, SH3BP2 antibody (sc-377020), and PLCγ2 (MAB3716) antibody followed by Western blotting shows co-precipitation of VAV2, SH3BP2, and PLCγ2. Immunoprecipitation using antibodies against each protein (lane labels on top) followed by Western blotting to probe each protein (indicated on left edge of gel images C and D) showed that SH3BP2-VAV2-PLCγ2 bound one another in untreated human podocytes. L, protein cell lysate; SC-Ab/SC, Santa Cruz Biotechnology (sc-377020) antibody; CA-Ab/CA, Canadian antibody against SH3BP2 from University of Toronto, Toronto, Ontario, Canada; F, flow through following immunoprecipitation; Neg, negative control; SH3BP2, Src homology 3-binding protein 2; VAV2, Rho-guanine nucleotide exchange factor VAV2; PLCγ2, phospholipase Cγ2; VAV2-IP, immunoprecipitation with VAV2 antibody; SH3BP2-IP, immunoprecipitation with SH3BP2 antibody; PLCγ2-IP, immunoprecipitation with PLCγ2 antibody.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts